• CytoDyn to seek regulatory approval for Covid-19 drug Vyrologix pharmaceutical-technology
    May 20, 2021
    CytoDyn is set to submit the results from the Phase III CD12 clinical trial of Vyrologix (leronlimab-PRO 140), seeking potential regulatory approval for the drug to treat severe to critically ill patients with Covid-19.
PharmaSources Customer Service